Tissue-invasive CMV disease is associated with poor prognosis during remission induction therapy for autoimmune inflammatory rheumatic diseases
CMV disease during remission induction therapy for AIIRDs is associated with higher antigenemia, more coincident infections, and poorer survival compared with CMV infection. Identifying the risk factors for CMV disease, including antigenemia and coincident infections, can improve patient outcomes.
Authors
- Hideki Oka (ORCID: https://orcid.org/0000-0002-9810-7644)
- Koichiro Ohmura (ORCID: https://orcid.org/0000-0003-2927-9159)
- Chisato Miyakoshi (ORCID: https://orcid.org/0000-0001-6882-7053)
- Shuji Sumitomo
Institutions
- Center for Clinical Research (United States) (US)
- Kobe City Medical Center General Hospital (JP)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-02-12
- DOI
- https://doi.org/10.3389/fimmu.2026.1696516
- Primary Topic
- Cytomegalovirus and herpesvirus research
- Type
- article
- Field-Weighted Citation Impact
- 0.00